Share Email Print

Proceedings Paper

Nanotechnology-based treatment for chemotherapy-resistant breast cancer
Author(s): Abraham H. Abouzeid; Niravkumar R. Patel; Ilya M. Rachman; Sean Senn; Vladimir P. Torchilin
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Background: Treatment of metastatic cancer remains a formidable clinical challenge. Better therapeutic options with improved tissue penetration and tumor cell uptake are urgently needed. Targeted nanotherapy, for improved delivery, and combinatory drug administration aimed at inhibiting chemo-resistance may be the solution. Purpose: The study was performed to evaluate the therapeutic efficacy of polymeric PEG-PE micelles, co-loaded with curcumin (CUR) and doxorubicin (DOX), and targeted with anti-GLUT1 antibody (GLUT1) against MDA-MB-231 human breast adenocarcinoma cells both in vitro and in vivo. Methods: MDA-MB-231 DOX-resistant cells were treated with non-targeted and GLUT1-targeted CUR and DOX micelles as a single agent or in combination. Tumor cells were also inoculated in female nude mice. Established tumors were treated with the micellar formulations at a dose of 6 mg/kg CUR and 1 mg/kg DOX every 2 d for a total of 7 injections. Results: CUR+DOX-loaded micelles decorated with GLUT1 had a robust killing effect even at low doses of DOX in vitro. At the doses chosen, non-targeted CUR and CUR+DOX micelles did not exhibit significant tumor inhibition versus control. However, GLUT1-CUR and GLUT1-CUR+DOX micelles showed a significant tumor inhibition effect with an improvement in survival. Conclusion: We showed a dramatic improvement in efficacy between the non-targeted and GLUT1-targeted formulations both in vitro and in vivo. Also, importantly, the addition of CUR to the micelle, has restored sensitivity to DOX, with resultant tumor growth inhibition. Hence, we confirmed that GLUT1-CUR+DOX micelles are effective in vitro and in vivo and deserve further investigation.

Paper Details

Date Published: 27 August 2014
PDF: 8 pages
Proc. SPIE 9166, Biosensing and Nanomedicine VII, 916606 (27 August 2014); doi: 10.1117/12.2064660
Show Author Affiliations
Abraham H. Abouzeid, Northeastern Univ. (United States)
Niravkumar R. Patel, Northeastern Univ. (United States)
Ilya M. Rachman, Immix Biopharma Inc. (United States)
Sean Senn, Immix Biopharma Inc. (United States)
Vladimir P. Torchilin, Northeastern Univ. (United States)

Published in SPIE Proceedings Vol. 9166:
Biosensing and Nanomedicine VII
Hooman Mohseni; Massoud H. Agahi; Manijeh Razeghi, Editor(s)

© SPIE. Terms of Use
Back to Top